Own Pain Relief Solution Store In Your City | Franchise Sales & Distribution Call us on 8691006638
Controlled thrombolytic therapy plays a vital role in the management of acute thrombotic conditions, particularly in clinical scenarios where gradual and closely monitored clot dissolution is required. Fibrinolytic agents are essential in supporting safe and effective restoration of blood flow in specialized treatment protocols.
KINASERA® (Streptokinase Injection) is developed by RAWIA INTERNATIONAL HEALTHCARE (RIHCA) in collaboration with leading pharmaceutical manufacturing partners and marketed through RAWIACARE. The 750,000 IU strength is positioned for controlled thrombolytic therapy, supporting healthcare professionals in delivering precise and monitored fibrinolytic treatment across hospitals, emergency departments, and specialized care units — To Share • To Care • To Inspire.
| Specifications Table | |
| Parameter | Details |
| Brand Name | KINASERA® |
| Generic Name | Streptokinase |
| Arabic Name | كيناسيرا ستربتوكيناز |
| Category | Thrombolytics |
| Therapeutic Area | Fibrinolytic Therapy |
| Dosage Form | Vial Injection |
| Strength | 750,000 IU |
| Volume | 1 Vial |
| Route / Type | Injectable |
| Developed By | RIHCA |
| Platform Name | RAWIACARE / RAWIACARE GLOBAL |
| Pulmonary Embolism (PE) |
| Deep Vein Thrombosis (DVT) |
| Arterial thrombosis |
| Controlled thrombolytic therapy |
| Hospital-based fibrinolytic protocols |
| It is used for controlled thrombolytic therapy in conditions such as pulmonary embolism and deep vein thrombosis. |
| It activates plasminogen, leading to the breakdown of fibrin clots and restoration of blood flow. |
| In clinical scenarios requiring gradual and monitored clot dissolution. |
| Hospitals, emergency units, and specialized care settings. |
| 750,000 IU, 1,500,000 IU |
